Loading...

Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer

An article in a recent edition of Current Oncology explored the validation of progression-free survival (pfs) as an endpoint in clinical trials of antineoplastic agents for metastatic colorectal cancer, metastatic renal cell carcinoma, and ovarian cancer. The support for pfs as a surrogate endpoint...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Cheema, P.K., Burkes, R.L.
Format: Artigo
Sprog:Inglês
Udgivet: Multimed Inc. 2013
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3615866/
https://ncbi.nlm.nih.gov/pubmed/23559882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.20.1226
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!